<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1559">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04355624</url>
  </required_header>
  <id_info>
    <org_study_id>20reamedcovid02</org_study_id>
    <nct_id>NCT04355624</nct_id>
  </id_info>
  <brief_title>Kidney Involvement in COVID-19 Disease (COVKID)</brief_title>
  <acronym>COVKID</acronym>
  <official_title>Characterization of Kidney Involvement in COVID-19 Disease: a French Multi-center Prospective Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Novel coronavirus disease (COVID-19) is a newly discovered contagious disease caused by
      SARS-CoV-2 virus, primarily manifesting as an acute respiratory illness with pneumonia, but
      can affect multiple organs such as kidney, heart, digestive tract, blood and nervous system.
      In previous reports of SARS and MERS-CoV infections, acute kidney injury was described in 5
      to 15% of patients and was associated with a high mortality rate (60-90%). Recent reports
      showed renal abnormalities in COVID-9 infected patients. A recent Chinese study also reported
      that acute kidney injury was an independent risk factor for mortality. However, the exact
      mechanism of kidney involvement remains unclear: sepsis-related cytokine storm or direct
      cellular injury from the virus. Also, kidney involvement has not yet been well characterized:
      heavy albuminuria, hematuria or interstitial nephropathy alone.

      A recent study identified viral RNA in kidney tissue and another study succeeded isolating
      SARS-CoV-2 from the urine sample of an infected patient. These data suggest that the kidney
      might be a target of this novel coronarivus.

      The sponsor suggests characterizing kidney involvement in SARS-CoV-2 infection.

      Study objectives are:

        -  To give an accurate characterization of kidney involvement in COVID-19

        -  To investigate the physiopathologic mechanism of kidney involvement in SARS-CoV-2
           infection

        -  To identify risk factors for kidney involvement in in SARS-CoV-2 infection

        -  To evaluate the impact of kidney involvement in in SARS-CoV-2 infection

        -  To assess the long-term health effect of kidney injury on survivors of in SARS-CoV-2
           infection
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2020</start_date>
  <completion_date type="Anticipated">July 30, 2020</completion_date>
  <primary_completion_date type="Actual">April 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Kidney involvement in COVID-19 disease</measure>
    <time_frame>until 3 months after discharge or death</time_frame>
    <description>Rate of kidney involvement in COVID-19 disease characterized by clinical and biological data</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physiopathologic mechanism of kidney involvement in SARS-CoV-2 infection</measure>
    <time_frame>until 3 months after discharge or death</time_frame>
    <description>biological data and histopathological data if available</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To identify risk factors for kidney involvement in in SARS-CoV-2 infection</measure>
    <time_frame>until 3 months after discharge or death</time_frame>
    <description>Rate of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the impact of kidney involvement in SARS-CoV-2 infection</measure>
    <time_frame>until 3 months after discharge or death</time_frame>
    <description>Legnth of hopital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the long-term health effect of kidney injury on survivors of SARS-CoV-2 infection in case of AKI KDIGO 2 or 3</measure>
    <time_frame>until 3 months after discharge</time_frame>
    <description>Recovery of Kidney fonction</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>COVID</condition>
  <condition>Kidney Injury</condition>
  <arm_group>
    <arm_group_label>ICU patients</arm_group_label>
    <description>COVID-19 patients admitted in Intensive Care Units</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non ICU patients</arm_group_label>
    <description>COVID-19 patients admitted in conventional units</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood and urine. Renal tissue only from post-portem kidney biopsies.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with confirmed COVID-19 disease
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed COVID-19 disease

          -  Age &gt; 18 years-old

        Exclusion Criteria:

          -  Age &lt; 18 years-old

          -  Pregnancy

          -  Patient with tutor- or curatorship or in prison

          -  Patients who had undergone renal replacement therapy (RRT) before admission
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sonia Boyer-Suavet</last_name>
    <phone>+ 33 92 03 55 10</phone>
    <email>boyer-suavet.s@chu-nice.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hajar Ouahmi</last_name>
    <phone>+ 33 92 03 55 10</phone>
    <email>ouahmi.h@chu-nice.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre hospitalier d'Antibes Juan les pins</name>
      <address>
        <city>Antibes</city>
        <zip>06600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe DESWARDT</last_name>
      <email>philippe.deswardt@ch-antibes.fr</email>
    </contact>
    <contact_backup>
      <last_name>Sonia BOYER-SUAVET</last_name>
      <email>sonia.boyer@ch-antibes.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de Cannes</name>
      <address>
        <city>Cannes</city>
        <zip>06400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-Marie BERTRAND</last_name>
      <email>PM.BERTRAND@ch-cannes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de Grasse</name>
      <address>
        <city>Grasse</city>
        <zip>06130</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-Marie BERTRAND</last_name>
      <email>PM.BERTRAND@ch-cannes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia Boyer-Suavet,</last_name>
      <email>boyer-suavet.s@chu-nice.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 17, 2020</study_first_submitted>
  <study_first_submitted_qc>April 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2020</study_first_posted>
  <last_update_submitted>May 12, 2020</last_update_submitted>
  <last_update_submitted_qc>May 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>no data sharing plan has been established</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

